Obscure gastrointestinal bleeding: diagnostic and therapeutic approach.
Obscure gastrointestinal bleeding (OGIB) is defined as an intermittent or continuous loss of blood in which the source has not been identified after upper endoscopy and colonoscopy. It constitutes a diagnostic and therapeutic challenge for the general internist and the gastroenterologist. This article provides an overview of the etiology, clinical presentation, and diagnostic modalities of OGIB including push enteroscopy, double balloon enteroscopy, wireless capsule endoscopy, enteroclysis, angiography, bleeding scanning with labeled red blood cells, and surgery with intraoperative enteroscopy. Therapeutic modalities including iron replacement, combined hormones, octreotide acetate, therapeutic endoscopy, and surgery are also discussed. In addition, a rational approach to patients with OGIB according to the clinical presentation is presented herein.
Concha
Ronald
R
Division of Gastroenterology, University of Miami, Miller School of Medicine/Mt. Sinai Medical Center, Miami Beach, FL 33140, USA.
Amaro
Rafael
R
Barkin
Jamie S
JS
D000465:Algorithms; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000792:Angiography; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D016145:Endoscopy, Digestive System; D004967:Estrogens / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006471:Gastrointestinal Hemorrhage / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D007501:Iron / Q000627:therapeutic use; D009780:Occult Blood; D015282:Octreotide / Q000627:therapeutic use; D011374:Progesterone / Q000627:therapeutic use; D013667:Technetium; D013792:Thalidomide / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000933:Antifibrinolytic Agents; D004967:Estrogens; D005765:Gastrointestinal Agents; D011374:Progesterone; D013792:Thalidomide; D013667:Technetium; D007501:Iron; D015282:Octreotide